

CITATION REPORT

List of articles citing

Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates

DOI: 10.1016/j.jval.2017.04.017
Value in Health, 2017, 20, 1074-1082.

Source: <https://exaly.com/paper-pdf/67138769/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
25	Economic burden of haemophilia B high in the US. <i>PharmacoEconomics & Outcomes News</i> , 2017 , 781, 14-14	0.1	
24	The socioeconomic burden of patients affected by hemophilia with inhibitors. <i>European Journal of Haematology</i> , 2018 , 101, 435-456	3.8	21
23	Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems. <i>Frontiers in Plant Science</i> , 2019 , 10, 261	6.2	6
22	The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. <i>Expert Review of Hematology</i> , 2020 , 13, 269-274	2.8	7
21	Economic burden of hemophilia A and B: a case in Iran. <i>Hematology</i> , 2020 , 25, 149-155	2.2	2
20	Characterisation of healthcare utilisation and cost of haemophilia care in real-life: A 4-year follow-up study in Finland. <i>Haemophilia</i> , 2021 , 27, e30-e39	3.3	
19	Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal. <i>International Journal of Environmental Research and Public Health</i> , 2021 , 18,	4.6	1
18	Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHES US and CHES US+ population surveys. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 143	4.2	6
17	Cost-of-illness studies in rare diseases: a scoping review. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 178	4.2	3
16	Health care resource utilization and cost burden of hemophilia B in the United States. <i>Blood Advances</i> , 2021 , 5, 1954-1962	7.8	3
15	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. <i>Blood</i> , 2021 , 138, 1677-1690	2.2	6
14	Expression of a human cDNA in moss results in spliced mRNAs and fragmentary protein isoforms. <i>Communications Biology</i> , 2021 , 4, 964	6.7	2
13	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. <i>Journal of Medical Economics</i> , 2021 , 24, 363-372	2.4	3
12	Assessment of monthly economic losses in Wuhan under the lockdown against COVID-19. <i>Humanities and Social Sciences Communications</i> , 2020 , 7,	2.8	18
11	Expression of a human cDNA in moss results in spliced mRNAs and fragmentary protein isoforms.		
10	Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B.. <i>Journal of Medical Economics</i> , 2022 , 1-21	2.4	
9	Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHES II study.. <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 148	4.2	0

8	Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHES-PAEDs study.. <i>Orphanet Journal of Rare Diseases</i> , 2022 , 17, 150	4.2	
7	Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHES II real-world burden of illness study in Europe.. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 521	4.2	0
6	Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates.. <i>Haemophilia</i> , 2022 ,	3.3	0
5	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia-Hematology Utilization Group Study Part VII (HUGS VII).. <i>Journal of Blood Medicine</i> , 2022 , 13, 229-241	2.3	1
4	Impact of Depression on Patients With Hemophilia: A Retrospective Case-Control Research. <i>Frontiers in Psychiatry</i> , 13,	5	
3	Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 818973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting. 2022 , 22,		
2	Costs and Impact of Disease in Adults with Sickle Cell Disease: A Pilot Study.		0
1	Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science. 2023 , 16, 87-106		9